

HSP Patients Leader Group
Madrid
2015 June 1



Philippe HANRIAT
President

Jean BENARD
Vice President
Scientific Adviser

23 years old

600 HSP affected families



- **Promote the recognition of our disease** in the French Society especially putting the stress on accessibility
- **Improve our quality of living**
- **Support research** : each year we donate about 25 000 E for HSP research project dealing either with genetics or with physiopathology)
- **Promote the recognition of all rare diseases**, in all country and worldwide

MEANS: CREATION OF NETWORKS


- ❑ Development : National ASL networking covering districts and France
- ❑ Integration : French Rare Diseases Alliance Federation
- ❑ Creation : Federation of Neurodegenerescence Diseases (FND):
HSP, French Associations **Friedreich & Cerebellar Syndrom**
 - Common Scientific Committee
 - Common Medical & ParaMedical Committees
recommendations and guidelines
 - 2 supports for quality of living :
 - ☎ Psychological phone line run by 2 psychologists entirely devoted to neurological syndromes
 - ☎ Phone line of management for social administrative issues.

- Web Site** (forthcoming reappraisal)
- Magazine “*Spastic*”**, twice a year (forthcoming is N° 74)
- News Letter** every 2 months
- Booklet “*To live with HSP*”** devoted to all aspects of HSP , in press to be issued oct 2015, sponsored by GrOUPAMA insurances Fundation
- Annual GA meetings** in Lyon, France
- Common meetings with FND on Ethics & Quality of Living**

The DNA School
at GENETHON



Double helix contemplation




Pr Giovanni STEVANIN at work...

**The ASL DONATIONS
to RESEARCH TEAMS
2007 > 2015**

YEAR	RESEARCH TEAM	PROJECT	DONATION (€)	RESULT or CONTRIBUTION
2007	Dr Amir BOUKRIS (Pr Giovanni STEVANIN lab, Salepétrière) Paris	Recessive SPG Genes identifications	25 000	<u>SPG 11 & SPG 15 identification</u>
2008	ASL Research Prizes Dr Coralie FASSIER & Anne TARADE (Pr Judith MELKI lab) Evry		4 000	Establishment of a <i>SPG4</i> ^{-/-} mice strain C.Fassier <i>et al.</i> Microtubules-targetting drugs rescue axional swellings in cortical neurons from Spastin-knock-out mice <i>Dis. Model. Mech.</i> 2013
2008	Laboratory of Dr Jamilé HAZAN, Pierre & Curie University Paris	Instalation of the lab: apparatus and reagents	10 000	
2009	Laboratory of Dr Jamilé HAZAN, Pierre & Curie University	Instalation of the lab: apparatus and reagents	25 000	
2010	Laboratory of Dr Jamilé HAZAN, Pierre & Curie University	Partial salary of Dr Coralie FASSIER post-doc: <i>SPG3A</i> physiopathology	25 000	<i>SPG3A</i> physiopathological mechanism: BMP signalling pathway at work. <i>Nature NeuroScience</i> 2010
2011	ASL Research Prize to Drs Jamile HAZAN & Coralie FASSIER	From genes to physiopathological mechanisms	8 000	Outstanding contributions: Discoveries of <i>SPG4</i> and sorting out physiopathology mechanisms associated to <i>SPG3A</i> & <i>SPG4</i>
2011	Laboratory of Pr Cyril GOIZET , Bordeaux	Energetic, mitochondrial, and lipidic metabolism in PSH	17 000	
2012	Laboratory of Pr Cyril GOIZET , Bordeaux	Energetic, mitochondrial, and lipidic metabolism in PSH	17 000	First step project towards the <i>SPG5</i> gene French project
2014	Laboratory of Dr Jamilé HAZAN, Pierre & Curie University	Disposables & Reagents for <i>SPG4</i> physiopathology project	8 000	Allison R., An ESCRT–spastin interaction promotes fission of promotes fission of recycling tubules from the endosome <i>J Cell Biol.</i> 2013
2014	Laboratory of Dr Fany MOCHEL & Pr Alexandra DÜRR ICM Salepétriere Paris	Metabolic therapeutic intervention for <i>SPG5</i> HSP patients	20 000	
2015	Laboratory of Dr Fany MOCHEL & Pr Alexandra DÜRR ICM Salepétriere Paris	Metabolic therapeutic intervention for <i>SPG5</i> HSP patients	20 000	
			179 000	

The FORTHCOMING DONATIONS
to FRENCH RESEARCH TEAMS
2016-2017

2016	Dr Coralie FASSIER (Dr HAZAN lab) on going request Not evaluated yet	HSP related to <i>SPG4</i> locus :physiopatholy and potential therapeutic targets	20 000
2016	Dr Guillaume BANNEAU (Pr Giovanni STEVANIN lab) on going request not yet approved by Administrative Committee	Partial Genotype/Phenotype Interface for European countries belonging to SPATAX Network	6 000
2017	Dr Coralie FASSIER (Dr HAZAN lab) on going request Not evaluated yet	HSP related to <i>SPG4</i> locus :physiopatholy and potential therapeutic targets	20 000



Zebra Fish

Our RESEARCH TEAMS



Dr Coralie FASSIER & Dr Jamilé HAZAN


Paris

SPG3A, SPG4 Physiopathology



SPATAX meeting , Paris 2012

Pr Cyril GOIZET,
Bordeaux
Energetic
Metabolism



Pr Giovanni STEVANIN, Paris
Gene identification SPG11 & SPG15



**The President
& the Vice President**



FND Federation



DNA School students



❑ **Use of genetic identification for progeny project of parents**

⇒ Prenatal testing

⇒ In vitro fertilization and embryos testings

❑ **Improvement of HSP Patients care and living**

⇒ Accessibility

⇒ Intercontinental good practices regarding physical training

❑ **Towards targeted treatment for patients**

⇒ SPG4 deficient

⇒ Metabolism deficient

Jean BENARD ABILITIES
« PRO and CON »


CON

- ***« I am not a business man and I am very bad fund raiser »***


PRO

- ***« Eager to afford my own to the HSP battle***
- ***Diplomat: able to put people working together***
- ***Perfectly aware of advances in HSP researches, able to afford advices on strategic approaches »***

- **Extreme genes heterogeneity reflects distinct physio-pathological mechanisms at work in the cortico-spinal neurone**




Physiopatology mechanisms from 34 genes
Klebe, Stevanin & Depienne. Rev. Neurol (in press)



Novario G. et al, *Science* 2014

- **SPG-encoded proteins, to exert their biological activity, interact between themselves or with other proteins**
- **SPG-encoded proteins form a biological network that, if not functional, also operate in other neurological diseases: cerebellum syndrome (CS) or Amyotrophic Lateral Syndrome. **A real advantage for fund raising: the more, the best !****
- **This can explain, in families, variations of clinical expression and may reflect observed “passage” from HSP to CS**



- Multiple therapeutic approaches that target the physiopathological mechanism at work, depending on the involved defective *SPG* gene
- Consequently, distinct cohorts numerous of patients must be obtained to test any therapeutic proposal